StockData
Immatics N.V. logo

Immatics N.V. (IMTX) stock

IMTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 1/30
$6.29+0.12 (+1.94%)

Close on Nov 17, 2026Market cap $843.31MP/E –Yield –

Earnings

Immatics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q1 FY2024
€30.27M
EPS, Q1 FY2024
-0.04 EUR
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Immatics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q1 FY2024ended Mar 31, 2024May 14, 2024before the open€30.27M–-0.04 EURRelease
Q4 FY2023ended Dec 31, 2023Mar 21, 2024before the open–––Release
Q4 FY2022ended Dec 31, 2022Mar 21, 2023before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Immatics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Immatics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Immatics filed with the SEC as exhibits to Form 8-K or 6-K

  1. 6-K
  2. 6-K
  3. 6-K
  4. 6-K
  5. 6-K
  6. 6-K
  7. 6-K
  8. 6-K
  9. 6-K
  10. 6-K
  11. 6-K
  12. 6-K
  13. 6-K
  14. 6-K
  15. 6-K

See a number that looks wrong?